DNA gyrase and topoisomerase IV are type IIa topoisomerases that are essential bacterial enzymes required to oversee the topological state of DNA during transcription and replication processes. Their ATPase domains, GyrB and ParE, respectively, are recognized as viable targets for small molecule inhibitors, however, no synthetic or natural product GyrB/ParE inhibitors have so far reached the clinic for use as novel antibacterial agents, except for novobiocin which was withdrawn from the market. In the present study, a series of substituted oxadiazoles have been designed and synthesized as potential DNA gyrase inhibitors. 
INTRODUCTION
The incidence of infections resistant to all currently used antibacterial drugs has increased dramatically in the past decade [1] . The emerging resistance extends to both Gram-positive and Gram-negative organisms and constitutes a serious threat to successful antibacterial therapy [2] . One approach to tackling this issue successfully is to develop novel agents that inhibit known and novel bacterial targets via unique binding sites or via novel modes of action [3] .
DNA gyrase and topoisomerase IV are bacterial type IIa topoisomerases and pivotal enzymes required in overseeing the topological state of DNA during transcription and replication processes [4] . While DNA gyrase is essential for the initiation of DNA replication, elongation of nascent DNA and the negative supercoiling of DNA during replication, topoisomerase IV is involved primarily in DNA decatenation at the end of replication [5] . The inhibition of one or both of these enzymes results in the disruption of DNA synthesis, in turn leading to cell death. DNA gyrase and topoisomerase IV are heterotetramers, formed by association of subunits GyrA and GyrB or ParC and ParE, respectively [6] [7] [8] . DNA gyrase and topoisomerase IV are clinically validated targets, their druggability being well established in two classes of antibiotics -the fluoroquinolones and aminocoumarins. The fluoroquinolones interact with the GyrA and ParC domain, while aminocoumarins target the GyrB and ParE domains [9] . Of note, DNA gyrase and topoisomerase IV enzymes act in an ATP-dependent manner, relying on their ATPase domains, GyrB and ParE, respectively, for providing the energy required for the extensive conformational changes [6] . Their ATP binding pockets exhibit high homology among bacteria, but at the same time low homology with eukaryotes [4] . They have been recognized early on as potential targets for small molecule inhibitors [7, 10, 11] , however, to date, no synthetic or natural product GyrB/ParE inhibitors since novobiocin which was withdrawn from the market have reached the clinic due to different issues such as resistance, toxicity and permeability [12] . The GyrB/ParE ATP-binding subunits, therefore, are still insufficiently exploited targets for the development of novel antibacterial agents [13] .
Novobiocin and clorobiocin belong to a class of structurally closely related naturally occurring antibiotics, the aminocoumarins (see Fig. 1 ). Clorobiocin features a pyrrole moiety replacing the carbamate group of novobiocin and a chlorine atom instead of a methyl group.
The most essential interaction between these aminocoumarins and the ATP-binding site is achieved in E. coli via Asp73 residue and the associated water molecule [7] . Cyclothialidines (see Fig. 1 ) constitute the second class of naturally occuring DNA gyrase ATPase inhibitors [14] [15] [16] . These provide proof of tolerance of the ATP binding site of DNA gyrase to significant chemical diversity [7] . The X-ray crystal structures of coumarins and cyclothialidines bound to the ATP-binding pocket of DNA gyrase further have reinforced that conclusion, revealing that the carbamate of novobiocin, the 2-carboxypyrrole of clorobiocin, and the phenol group of cyclothialidine, are all able to interact with the Asp73 residue and its hydrogen-bonded conserved water molecule [6] . The crystal structure of DNA gyrase B was first solved by Wigley in 1991, laying the groundwork for further research in this field [17] . The X-ray structure information on the binding modes of cyclothialidine and novobiocin to the ATP binding site of GyrB [18, 19] as well as the ligand-based inhibitor design [15, 16] had established a broad knowledge of the structure-activity relationships (SAR), providing a strong basis for the rational design of novel inhibitors and at the same time enabling further optimization of lead structures. The binding modes of the reported inhibitors revealed an overlapping site of interaction, namely a set of hydrogen bonds provided by Asp73 and an associated conserved water molecule. This interaction is essential, and almost indispensable. Nevertheless, other unique structural and electronic characteristics of the binding-site pocket have also been taken into account in the design process. The common structural features of synthesized inhibitors also include functionalities making use of interactions with (i) Arg136; (ii) an additional hydrophobic pocket composed of Val71, Val43, Val167, and Ala147; (iii) a hydrophobic floor consisting of Pro79, Ile78 and Ile94 and (iv) and a π-stacking ceiling formed by Arg76 in a Glu50-Arg76 salt bridge. The ligand-based and fragment-based approaches as well as the targeted screening programs have identified numerous GyrB inhibitors with diverse scaffolds, such as novobiocin and cyclothialidine analogs [15, 16, 20] , arylaminotriazines [21] , arylaminopyrimidines [2] , indazoles [22] , pyrazolopyridones [23] , pyrrolopyrimidines [11, 13] , pyridylureas [24] , pyrrolamides [25] and tricyclic pyrimidinoindoles [26] , thus providing several additional starting points for medicinal chemists (structures are shown in Fig. 2 ).
Currently, there is a pressing need for new antibacterial compounds [27] . Compound XIV (Fig. 3) , a low nanomolar GyrB inhibitor based on a thiazole-piperidine central core has recently been disclosed as part of a series of promising pyrrolamide GyrB inhibitors [9] . Its development, however, was discontinued mostly due to unfavorable pharmacokinetics. Therefore, we explored possible replacements of the thiazole-piperidine core of XIV to find another scaffold that could provide different SAR and optimization opportunities.
Oxadiazoles are considered important constituents of biologically active compounds, exhibiting a wide range of effects, which makes them attractive building blocks for a variety of purposes [28] [29] [30] . The main objective of the present study was to identify small molecule inhibitors of DNA gyrase based on a novel phenyl-substituted oxadiazole central scaffold by utilising their structural similarity to the known pyrrolamide XIV.
RESULTS AND DISCUSSION

Design
Our design was based on the structures of the recently disclosed series of pyrrolamide GyrB inhibitors carrying a thiazole-piperidine central core and represented by compound XIV [9] .
Making use of both ligand-based as well as structure-based approaches, we chose this inhibitor as lead and designed a small library of its analogs based on a substituted 5-phenyl-1,2,4-oxadiazole central scaffold (Fig. 3) . The thiazole-carboxylic acid moiety was bioisosterically replaced by an oxadiazole-carboxylic acid. The aromatic nature of this heterocycle is key for optimizing π-stacking with Arg76 and hydrogen bond interactions with Arg136, while the pendant carboxylic acid function provides an additional interaction with Arg136. The Glu50-Arg76 salt bridge has also been taken into account, as it is prone to a π-cation interaction with the oxadiazole moiety of the inhibitors. The pyrrole NH group of XIV has been shown to interact with the Asp73-water H-bond motif in the GyrB ATP-binding pocket, indicating a certain degree of similarity of this series to clorobiocin and kibdelomycin [31] . Of note, some of the reported ATP-competitive DNA gyrase inhibitors (e.g. clorobiocin) feature substituted pyrrole moieties in their structures. It has been demonstrated that, by attaching small lipophilic groups to the pyrrole ring, stronger interactions with the left-hand side lipophilic pocket of GyrB can be achieved. Similarly, several DNA gyrase inhibitors possessing pyrrole, dibromopyrrole and bromopyrrole moieties in their structures have been identified [32] [33] [34] [35] [36] . Thus, the 5-methyl-3,4-dichloropyrrole moiety of the parent compound was replaced by various heterocyclic moieties, such as indole, Moreover, 19 was also predicted to form two hydrogen bonds -one with Asp73 side chain and the other with the conserved water molecule bridged to Asp73 carboxylate. In addition, the oxadiazole nucleus is predicted to form cation-π interaction with Arg76 side chain, further reinforcing the binding, while it also forms a hydrogen bond with Arg136 side chain (Fig. 4a) .
The terminal carboxylate bound to the oxadiazole ring was predicted to form two additional hydrogen bonds with Arg136, thus additionally constraining the inhibitor in the binding site (Fig. 4a) .
Synthesis of the second series of compounds was also guided by molecular docking of candidate molecules into the DNA gyrase ATP-binding site. These compounds feature a methylene/imine linker connecting the phenyl and 1,2,4-oxadiazole moieties, inserted in the central scaffold. By inserting a flexible linker, we attempted to direct the carboxylic acid functionality toward the Arg136 in the binding site, as predicted by molecular docking of compound 34 (Fig. 4b) . In this case, the imine hydrogen was predicted to form an additional hydrogen bond with Gly101, as seen in the case of GyrB inhibitors discovered by Brvar et al [39] . The indole, 4,5-dibromopyrrole and 5-methyl-3,4-dichloropyrrole moieties, which proved to be the most appropriate to fit the left-hand side hydrophobic pocket of DNA gyrase, have been retained in the structures of this novel series of inhibitors (Fig. 3 ).
Chemistry
The starting esters 1-5 were obtained by coupling the corresponding carboxylic acids with ethyl m-aminobenzoate using the standard TBTU methodology. The subsequent alkaline hydrolysis of esters 1-5 yielded the acylated derivatives of m-aminobenzoic acid 6-10. The latter were coupled with ethyl 2-oximinooxamate (Scheme 1) using TBTU-coupling conditions (adapted from [40] ). The afforded O-acyl amidoximes were immediately subjected to cyclization conditions using KF in 1,4-dioxane at 110 °C, thereby giving the corresponding ethyl 1,2,4-oxadiazole-3-carboxylates 11-15. Final deprotection of ethyl esters was achieved by alkaline hydrolysis using 1M NaOH/THF mixture [41] , affording the final compounds, the [43] .
In the following step, the 5-trichloromethyl derivative 32 underwent a nucleophilic displacement with p-phenylenediamine in the presence of DMAP in refluxing chloroform to afford compound 33 (adapted by [44] Screening of the second-generation of compounds (see Table 1 
Antibacterial activity
Oxadiazoles 18 
CONCLUSIONS
In conclusion, two series of substituted oxadiazoles have been prepared originating from the structure XIV. Iterative cycles of structure-based optimization resulted in compound 35 which Furthermore, it also exhibited a modest inhibition against Enterococcus faecalis (MIC 90 = 75 µM). Overall, the results offer a valuable insight into the structural requirements of substituted oxadiazoles for DNA gyrase inhibition and thus provide a good foundation for further research in this field.
EXPERIMENTAL SECTION
Materials and methods
Chemicals were obtained from Acros, Sigma-Aldrich and TCI, and used without further purification. Analytical TLC was performed on Merck 60 F254 silica gel plates (0.25 mm), using visualization with ultraviolet light and ninhydrin. Column chromatography was carried out on silica gel 60 (particle size 240-400 mesh). Melting points were determined on a Reichert hot stage microscope and are uncorrected. 1 H-and 13 C-NMR spectra were recorded at 400 MHz and 100 MHz, respectively, on a Bruker AVANCE III spectrometer in DMSO-d 6 ,
MeOD or CDCl 3 solution with TMS as the internal standard. Spectra were assigned using gradient HSQC and HMBC techniques. IR spectra were recorded on a Perkin-Elmer 1600 FT-IR spectrometer. Mass spectra were obtained using a VG-Analytical Autospec Q mass spectrometer. Microanalyses were performed on a 240 C Perkin-Elmer CHN analyzer. HPLC analyses were performed on an Agilent Technologies HP 1100 instrument with G1365B UV-VIS detector (254 nm), using a Luna C18 column (4.6 × 150 mm) at a flow rate of 1 mL/min.
The eluent was a mixture of 0.1% TFA in water (A) and acetonitrile (B), with a gradient of 30% B to 80% B from 0-30 minutes and 80% B to 90% B from 30-33 minutes.
General procedures
Formation of 1,2,4-oxadiazoles
To a stirred solution of carboxylic acid derivative (1.0 eq) in dried tetrahydrofuran (THF), diisopropylethylamine (3.0 eq) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) (1.1 eq) were added. After stirring for 45 minutes ethyl 2-oximinooxamate (1.0 eq) and a catalytic amount of 4-dimethylaminopyridine (DMAP) (0.1 eq) were added and the mixture stirred at room temperature for an additional 2 h. The solvent was then removed in vacuo to afford the crude product. This was used without purification in the next step in which it was dissolved in dry 1,4-dioxane (5 mL). Potassium fluoride (3.0 eq) was then added and the mixture was heated at 80 °C for 24 h. On completion, the reaction mixture was concentrated in vacuo and the residue purified by flash silica gel column chromatography (gradient elution; starting eluent: hexane/ethyl acetate 3:1 v/v) to afford the desired compounds 11-15.
Acidolytic cleavage of Boc protecting groups and the subsequent TBTU-mediated coupling
To an ice-chilled stirred mixture of trifluoroacetic acid (TFA) and dichloromethane (v/v 1/5, 5 mL) Boc-protected compound (1.0 eq) was added and the mixture allowed to warm to room temperature. After 3 h the reaction was complete and the solvent was evaporated in vacuo.
The residue was washed three times with diethyl ether giving a crude ammonium salt which was dissolved in dichloromethane followed by the addition of diisopropylethylamine (1.0 eq).
In a parallel reaction, to a stirred solution of indole-2-carboxylic acid or 4,5-dibromo-pyrrole-2-carboxylic acid (1.0 eq) in dry dichloromethane (10 mL), diisopropylethylamine (3.0 eq) and TBTU (1.1 eq) were added. After stirring for 45 minutes the solution of free amine in dichloromethane was added at 0 °C, and the mixture was allowed to warm to room temperature. Stirring was continued for 48 h. On completion, the reaction mixture was diluted with dichloromethane (30 mL) then washed with 1M HCl (2 × 20 mL), water (20 mL), saturated NaHCO 3 solution (2 × 20 mL), water (20 mL) and dried over anhydrous Na 2 SO 4 .
The solvent was concentrated in vacuo and the residue purified by flash silica gel column chromatography (gradient elution; starting eluent: hexane/ethyl acetate 2:1 v/v) to afford the corresponding amides 22, 28 and 29.
TBTU-mediated coupling
To a stirred solution of carboxylic acid (1.0 eq) in dry dichloromethane (10 mL), diisopropylethylamine (3.0 eq) and TBTU (1.1 eq) were added. After stirring for 45 minutes ethyl m-aminobenzoate was added at 0 °C, and the mixture allowed to warm to room temperature; stirring then continued for 48 h. On completion, the reaction mixture was diluted with dichloromethane (30 mL) then washed with 1M HCl (2 × 20 mL), water (20 mL), saturated NaHCO 3 solution (2 × 20 mL), water (20 mL) and dried over anhydrous Na 2 SO 4 .
The solvent was concentrated in vacuo to afford the desired amides 1-5.
Alkaline hydrolysis
To a solution of the corresponding ester (1 eq) in THF, 1M NaOH (5 eq) was added and the reaction mixture stirred at room temperature for 5 h. THF was evaporated under vacuum and the resulting aqueous solution neutralized with 1M HCl until the product started to precipitate.
The product was filtered off, then dried to afford the desired acids 6-10. 
Characterization of compounds
Ethyl 3-(1H-pyrrole-2-carboxamido)benzoate (1
Ethyl 3-(1H-indole-2-carboxamido)benzoate (4
3-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzoic acid (8).
3-(1H-indole-2-carboxamido)benzoic acid (9)
.
3-(5-Fluoro-1H-indole-2-carboxamido)benzoic acid (10
Ethyl 5-(3-(1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylate (11).
Synthesized according to the general procedure for acidolytic cleavage of Boc protecting groups and the subsequent TBTU-mediated coupling. 
Ethyl 5-(3-(4-bromo-1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylate (12
Ethyl 5-(3-(4,5-dibromo-1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylate (13
Ethyl 5-(3-(1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylate (14).
Ethyl 5-(3-(5-fluoro-1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylate
5-(3-(1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid (16).
Synthesized according to the general procedure for alkaline hydrolysis described in [41] . 
5-(3-(4-Bromo-1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid (17)
. Synthesized according to the general procedure for alkaline hydrolysis described in [41] . 
5-(3-(4,5-Dibromo-1H-pyrrole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid (18)
5-(3-(1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid (19).
Synthesized according to the general procedure for alkaline hydrolysis described in [41] . HPLC: t r = 11.81 min (98.3% at 254 nm).
5-(3-(5-Fluoro-1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxylic acid (20)
Ethyl 5-(3-(1H-indole-2-carboxamido)phenyl)-1,3,4-oxadiazole-2-carboxylate (22).
Synthesized as described in [42] . Yellow amorphous powder; m.p. 225-227 °C. 
N-(3-(1,3,4-oxadiazol-2-yl)phenyl)-1H-indole-2-carboxamide (23).
5-(3-(1H-indole-2-carboxamido)phenyl)-1,3,4-oxadiazole-2-carboxamide (24).
Synthesized according to the general procedure for aminolysis described in [40] . White amorphous powder; m.p. 264-268 °C. t r = 9.98 min (100.0% at 254 nm).
5-(3-(1H-indole-2-carboxamido)phenyl)-1,2,4-oxadiazole-3-carboxamide (25).
Synthesized according to the general procedure for aminolysis described in [40] . HPLC: t r = 11.23 min (100.0% at 254 nm).
5-(3-(1H-indole-2-carboxamido)phenyl)-N-hydroxy-1,2,4-oxadiazole-3-carboxamide (26).
Synthesized according to the procedure described in [40] . White amorphous powder; m.p. 187-190 °C. 
Ethyl 5-(4-(1H-indole-2-carboxamido)benzyl)-1,2,4-oxadiazole-3-carboxylate (28).
Synthesized according to the general procedure for acidolytic cleavage of Boc protecting 
5-(4-(1H-indole-2-carboxamido)benzyl)-1,2,4-oxadiazole-3-carboxylic acid (30).
5-(4-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzyl)-1,2,4-oxadiazole-3-carboxylic acid (31).
Synthesized according to the general procedure for alkaline hydrolysis described in [41] . Compound 35 that showed >80% inhibition against E. faecalis in the primary screen was tested further at 10 different concentrations to confirm its activity and to determine the MIC 90 concentration (lowest concentration inhibitingthe growth by >90%). Ciprofloxacin (ICN Biomedicals Inc., USA) was used as positive control on every assay plate at MIC 90 concentration.
Molecular Modeling.
Ligand and Protein Preparation. Three-dimensional models of designed compounds were built in ChemBio3D Ultra 13.0 [46] Their geometries were optimized using MMFF94 [47] force field and partial atomic charges were added. Energy was minimized until the gradient value was smaller than 0.001 kcal/(mol Å). The optimized structure was further refined with GAMESS interface in ChemBio3D Ultra 13.0 using the semiempirical PM3 method, QA optimization algorithm and Gasteiger Hückel charges for all atoms for 100 steps [47] .
Molecular docking calculations were performed using FlexX [48, 49] , as available in LeadIT [37] , running on four octal core AMD Opteron CPU processors, 16 GB RAM, two 750 GB hard drives, running 64-bit Scientific Linux 6.0. Receptor was prepared in a LeadIT graphical user interface using the Receptor wizard. Amino acid residues within a radius of 7 Å around the ligand from the X-ray structure (PDB entry: 4DUH [39] ) were defined as the binding site.
Hydrogen atoms were added to the binding site residues and correct tautomers and protonation states were assigned. Water molecules, except HOH614, and the ligand were deleted from the crystal structure.
Ligand Docking. The FlexX molecular docking program, as available in LeadIT [37] , was used for ligand docking. A hybrid algorithm (enthalpy and entropy driven ligand binding) was 
